Form 8-K - Current report:
SEC Accession No. 0001437749-25-002747
Filing Date
2025-02-04
Accepted
2025-02-04 16:58:38
Documents
14
Period of Report
2025-01-30
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nby20250203_8k.htm   iXBRL 8-K 48644
  Complete submission text file 0001437749-25-002747.txt   186065

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nby-20250130.xsd EX-101.SCH 3400
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nby-20250130_def.xml EX-101.DEF 11420
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nby-20250130_lab.xml EX-101.LAB 15309
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nby-20250130_pre.xml EX-101.PRE 11580
16 EXTRACTED XBRL INSTANCE DOCUMENT nby20250203_8k_htm.xml XML 2849
Mailing Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608
Business Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 (510) 899-8800
NovaBay Pharmaceuticals, Inc. (Filer) CIK: 0001389545 (see all company filings)

EIN.: 680454536 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33678 | Film No.: 25589290
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)